Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

11/14/24 1:22:38 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $GBIO alert in real time by email

SC 13G/A 1 gbio13gasep24.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) GENERATION BIO CO (Name of Issuer) COMMON STOCK (Title of Class of Securities) 37148K100 (CUSIP NUMBER) September 30, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 9,106,609 6. Shared Voting Power* 0 7. Sole Dispositive Power* 9,351,590 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 9,351,590 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 14.0% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: GENERATION BIO CO Item 1(b) Address of Issuer's Principal Executive Offices: 301 BINNEY STREET, CAMBRIDGE, MASSACHUSETTS 02142 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. (Price Associates) Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 37148K100 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class Not Applicable Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) [T. ROWE PRICE NEW HORIZONS FUND ]: T. ROWE PRICE NEW HORIZONS FUND, of which T. ROWE PRICE ASSOCIATES, INC. is the investment adviser, holds the securities reported herein in their investment portfolio managed by T. ROWE PRICE ASSOCIATES, INC. and such funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities that they hold. T. ROWE PRICE NEW HORIZONS FUND has an interest in 5,341,800 of the class reported herein representing 8.0% of the class. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: November 14, 2024 Signature: /s/ Ellen York Name & Title: Ellen York, Vice President 09/30/2024

Get the next $GBIO alert in real time by email

Recent Analyst Ratings for

$GBIO

Date	Price Target	Rating	Analyst
8/13/2025	$7.00	Outperform → Neutral	Wedbush
10/19/2023		Outperform → Market Perform	TD Cowen
11/8/2022	$9.00	Buy	Canaccord Genuity
12/15/2021	$40.00 → $10.00	Market Outperform	JMP Securities
12/15/2021	$50.00 → $27.00	Buy	Needham
12/14/2021		Outperform → Mkt Perform	William Blair

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

11/14/24 1:22:38 PM ET

$GBIO

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $GBIO alert in real time by email

Recent Analyst Ratings for

$GBIO

Date	Price Target	Rating	Analyst
8/13/2025	$7.00	Outperform → Neutral	Wedbush
10/19/2023		Outperform → Market Perform	TD Cowen
11/8/2022	$9.00	Buy	Canaccord Genuity
12/15/2021	$40.00 → $10.00	Market Outperform	JMP Securities
12/15/2021	$50.00 → $27.00	Buy	Needham
12/14/2021		Outperform → Mkt Perform	William Blair

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$GBIO

Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$GBIO

$GBIO
Press Releases

Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results

Generation Bio Announces 1-for-10 Reverse Stock Split

Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

$GBIO
Analyst Ratings

Generation Bio downgraded by Wedbush with a new price target

Generation Bio downgraded by TD Cowen

Canaccord Genuity initiated coverage on Generation Bio with a new price target

$GBIO
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Generation Bio Co.

SEC Form 10-Q filed by Generation Bio Co.

Generation Bio Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$GBIO
Insider Purchases

Director Quinn Anthony G. bought $203,209 worth of shares (210,791 units at $0.96), increasing direct ownership by 238% to 299,286 units (SEC Form 4)

Appelhans Dannielle bought $14,339 worth of shares (8,000 units at $1.79), increasing direct ownership by 5% to 12,637 units (SEC Form 4)

Appelhans Dannielle bought $18,000 worth of shares (12,000 units at $1.50) (SEC Form 4)

$GBIO
Insider Trading

CHIEF OPERATING OFFICER Paone Antoinette covered exercise/tax liability with 468 shares and converted options into 1,592 shares, increasing direct ownership by 3% to 35,465 units (SEC Form 4)

CHIEF LEGAL OFFICER Howze Yalonda converted options into 3,347 shares and covered exercise/tax liability with 983 shares, increasing direct ownership by 13% to 21,101 units (SEC Form 4)

Chief Financial Officer Conway Kevin John converted options into 587 shares and covered exercise/tax liability with 173 shares, increasing direct ownership by 2% to 18,273 units (SEC Form 4)

$GBIO
Leadership Updates

Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results

Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer

$GBIO
Large Ownership Changes